# Dasatinib for the Treatment of Moderate and Severe COVID-19

> **NCT04830735** · PHASE2 · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **DRUG:** Dasatinib Anhydrous
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT04830735
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-05
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI decided not to pursue study
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830735, "Dasatinib for the Treatment of Moderate and Severe COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04830735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*